Filing Summary: Fresenius Medical Care AG & Co. KGaA
Business Context and Reporting Period
This Form 6-K, filed on August 2, 2022, reports the second-quarter results for the period ending June 30, 2022. The filing serves as a conduit for a press release (Exhibit 99.1) and a complete overview of financial figures for the second quarter and the first six months of 2022 (Exhibit 99.2).
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached exhibits (99.1 and 99.2) referenced in the report.
The Company utilizes the following non-GAAP financial measures to supplement IFRS results:
- EBITDA (Operating income excluding interest, taxes, depreciation, and amortization)
- Adjusted EBITDA
- Free Cash Flow
- Net Leverage Ratio (Net debt to adjusted EBITDA)
- Results presented in constant currency
Reconciliations of these non-GAAP measures to the most comparable IFRS measures are included in the attached financial statements.
Material Changes and Outlook
The filing text does not explicitly detail material changes versus prior periods, specific guidance, management commentary, risks, or unusual items. These details are located in the attached press release and financial overview exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2022 revenue, EBITDA, and free cash flow figures.
- Examine Exhibit 99.2 for the complete financial overview of the first six months of 2022.
- Verify the reconciliation tables for non-GAAP measures (EBITDA, Adjusted EBITDA, Net Leverage Ratio) against IFRS standards.
- Check the press release for management commentary on constant currency impacts and any specific risks or contingencies.